From: The emergency department care of the cannabis and synthetic cannabinoid patient: a narrative review
System/organ class | Percentage of non-serious adverse events | |
---|---|---|
cannabinoid group | control group | |
Nervous system disordersa | 36.7 | 31.1 |
Gastrointestinal disordersa | 16.4 | 15.0 |
General disorders | 14.1 | 17.9 |
Psychiatric disordersa | 11.1 | 7.4 |
Musculoskeletal disorders | 7.2 | 10.6 |
Renal and urinary disorders | 5.1 | 8.2 |
Infections | 2.9 | 4.3 |
Eye disordersa | 2.3 | 1.0 |